Lumida
/GYRE
⌘K
Gyre Therapeutics Inc

Gyre Therapeutics Inc

GYRE
$6.73USD↓-0.15%-0.01 today

MARKET CAP

713.6M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $7

52W RANGE

$5
$9

AI Summary

Stalk
StalkMedium

GYRE is in Stage 2 advancing with a down long-term trend but has formed an emerging HH/HL sequence and a momentum breakout, signaling medium-term bullish asymmetry. However, price is extended above the rising 9EMA and 21EMA and facing the declining 200 DMA, suggesting entries should be deferred. Preferred execution zones are pullbacks into the rising short-term EMAs or near the recent breakout support area. The long-term downtrend under the 200-day SMA remains intact, posing structural risk until cleared and held.

  • ↑China liver-fibrosis trial shows promising efficacy signals in under-served market.
  • ↑Full-year revenue guidance reaffirmed despite wider Q2 loss, highlighting management confidence.
  • ↓Q2 revenue missed expectations and loss per share widened sequentially.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a biopharmaceutical company primarily focused on developing innovative therapies for life-threatening diseases. The company is particularly engaged in addressing liver diseases, with notable emphasis on liver fibrosis treatment. Gyre operates primarily in the biotechnology segment of the healthcare sector, where it looks to leverage emerging market opportunities in regions such as China. The company aims to address considerable unmet medical needs, positioning itself favorably within the industry during the ongoing focus on healthcare innovation and drug development.

Bull says

  • ↑China liver-fibrosis trial shows promising efficacy signals in under-served market.
  • ↑Full-year revenue guidance reaffirmed despite wider Q2 loss, highlighting management confidence.
  • ↑Positive growth and earnings revision trends underscore analyst optimism.
  • ↑High sensitivity to rising interest rates may ease financing access.
  • ↑Niche focus on liver fibrosis creates potential moat against peers.

Bear says

  • ↓Q2 revenue missed expectations and loss per share widened sequentially.
  • ↓Negative profitability factor underscores ongoing struggle to generate returns.
  • ↓Low earnings yield and poor liquidity position threaten cash runway.
  • ↓Elevated leverage risk adds pressure amid cash-intensive clinical trials.
  • ↓Moderate short interest reflects market skepticism on outlook.